![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Evaluation of Ritonavir-boosted Elvitegravir PK upon Co-administration with a Second Potent CYP3A inhibitor, Ketoconazole
|
|
|
Reported by Jules Levin
International Workshop on Clinical Pharmacology of HIV Therapy April 7-9, 2010 Sorrento, Italy
P. German, AA Mathias, S West, S Chuck, BP Kearney
Gilead Sciences, Inc., Foster City, CA 94404
![](../images/042310/042310-7/image002.gif)
![](../images/042310/042310-7/image004.gif)
![](../images/042310/042310-7/image006.gif)
![](../images/042310/042310-7/image008.gif)
![](../images/042310/042310-7/image010.gif)
![](../images/042310/042310-7/image012.gif)
![](../images/042310/042310-7/image014.gif)
![](../images/042310/042310-7/image016.gif)
![](../images/042310/042310-7/image018.gif)
![](../images/042310/042310-7/image020.gif)
![](../images/042310/042310-7/image022.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|